Pulsar Therapeutics

Pulsar Therapeutics is a biotechnology company focused on the development of a proprietary supramolecular nanoparticle (SMNP) platform for the delivery of diverse therapeutic payloads. The company's technology is designed to enable the efficient delivery of vaccines, antibodies, and other biologics, with a particular emphasis on overcoming traditional delivery barriers in oncology and infectious diseases. Pulsar was founded based on research from UCLA and has established strategic licensing agreements with Sorrento Therapeutics to advance its nanoparticle technology. The company aims to leverage its platform to create next-generation therapeutics with improved targeting and efficacy profiles.